Clinical Trials Logo
  1. Home
  2. Ovarian Epithelial Cancer
  3. NCT02981901
  4. Details
NCT02981901 Clinical Trial

Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

Ovarian Epithelial Cancer Clinical Trial

— Ovaire01  

Official title:
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02981901
Other study ID # Ovaire01
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 2017
Est. completion date December 2019

Study information
Verified date August 2018
Source Centre Leon Berard
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts.

Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit.

To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 376
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Ovarian epithelial cancer initially diagnosed in 2012

- Age > 18 years old

- Residency in France (Rhône-Alpes region, District of Calvados and Cotes d'Or)

- First-line ovarian epithelial cancer

Exclusion Criteria:

- Relapsed ovarian epithelial cancer

- Non epithelial ovarian cancer

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Patient with ovarian epithelial cancer

Locations
Country Name City State
France Calvados registry Caen
France Côte d'or registry Dijon
France Oveval Lyon

Sponsors (3)
Lead Sponsor Collaborator
Centre Leon Berard Cancer Calvados registry, Cancer Côte d'or registry

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incremental cost-effectiveness ratio expressed in cost per relapse-free year gained To perform a cost-effectiveness analysis in order to evaluate the most efficient organization for ovarian cancer in 1st line ot treatment 2 years after diagnosis
Secondary Incremental cost-effectiveness ratio expressed in cost per QALY(Quality-Adjusted Life Year) gained. 2 years after diagnosis
Secondary Budget impact analysis Cost assessment performed retrospectively for each patient: hospital stays, visits and other health-related costs will be identified and measured based on the French national Health Insurance perspective.
QALY (Quality-Adjusted Life Year)		 2 years after diagnosis
Secondary Relapse-free survival (RFS) RFS will be assessed 2 years after diagnosis
See also
  Status Clinical Trial Phase
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Active, not recruiting NCT01456065 - Safety of Active Immunotherapy in Subjects With Ovarian Cancer Phase 1
Recruiting NCT06404671 - Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Not yet recruiting NCT03220932 - Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer Phase 3
Not yet recruiting NCT05937620 - Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer N/A
Completed NCT02107937 - Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma Phase 2
Completed NCT02107950 - Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma Phase 2
Completed NCT02039388 - Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma N/A
Completed NCT01806350 - Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors N/A
Recruiting NCT03349463 - Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Phase 4
Completed NCT04823871 - Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing N/A
Completed NCT02518256 - Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity N/A
Active, not recruiting NCT03078400 - Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Phase 1
Completed NCT02489903 - RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Phase 2
Not yet recruiting NCT02435186 - p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Phase 2
Recruiting NCT04029909 - A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Phase 1
Recruiting NCT05498597 - AMT-151 in Patients With Selected Advanced Solid Tumours Phase 1
Suspended NCT02742428 - Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer N/A
Completed NCT02062697 - Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes. N/A